Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly save search
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
Published: 2023-01-10 (Crawled : 17:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.24%
H: 1.21%
C: 1.07%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.38%
H: 9.79%
C: 7.34%
disease
Veru Reports Fiscal 2023 First Quarter Financial Results
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.05%
H: 1.9%
C: 0.26%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -13.26%
H: 2.92%
C: -10.79%
financial results
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.85%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 1.31%
H: 0.81%
C: -4.52%
report financial results
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-06-24 (Crawled : 21:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
| Email alert
Add to watchlist
VERU | $1.365 -3.87% 1.7M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants
Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -1.49%
H: 1.13%
C: 0.07%
global conference
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-19 (Crawled : 17:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting respiratory review authorization
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk
Published: 2022-09-19 (Crawled : 17:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting review authorization
Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022
Published: 2022-09-21 (Crawled : 13:20) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.24%
H: 1.17%
C: -1.5%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -0.84%
H: 0.17%
C: -9.05%
conference
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-11-10 (Crawled : 02:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -58.83%
H: 25.89%
C: 12.78%
covid-19 fda risk sabizabulin meeting respiratory authorization update
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-10-04 (Crawled : 21:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.48%
H: 1.69%
C: 1.06%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -2.32%
H: 0.45%
C: -2.7%
nasdaq grants
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
Published: 2022-11-28 (Crawled : 14:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.49%
H: 1.67%
C: 0.64%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -2.14%
H: 5.56%
C: -1.28%
report year financial results
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-07-12 (Crawled : 21:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.49%
H: 0.83%
C: 0.14%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -2.0%
H: 14.15%
C: 8.44%
nasdaq grants
European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries
Published: 2022-07-27 (Crawled : 15:20) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.78%
H: 0.57%
C: -0.01%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.81%
H: 3.05%
C: 1.2%
covid-19 treatment sabizabulin review initiated
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-08-09 (Crawled : 15:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.86%
H: 0.53%
C: -0.68%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -0.5%
H: 2.25%
C: -4.17%
covid-19 treatment risk sabizabulin respiratory presentation study
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Published: 2022-07-25 (Crawled : 12:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: 0.85%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 3.41%
H: 0.07%
C: -8.65%
covid-19 treatment sabizabulin application review authorization
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-08-12 (Crawled : 21:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
| Email alert
Add to watchlist
VERU | $1.365 -3.87% 1.7M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
Published: 2022-08-22 (Crawled : 13:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.15%
H: 1.08%
C: 0.25%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 5.44%
H: 3.53%
C: -7.93%
covid-19 treatment sabizabulin granted
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
Published: 2022-08-19 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.25%
H: 2.6%
C: 1.66%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -3.19%
H: 7.78%
C: -3.37%
covid-19 disease international
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.